{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:58:27Z","timestamp":1780480707679,"version":"3.54.1"},"reference-count":41,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,5,21]]},"abstract":"<jats:p>\n            Omadacycline is a novel aminomethylcycline with activity against Gram-positive and -negative organisms, including\n            <jats:named-content content-type=\"genus-species\">Haemophilus influenzae<\/jats:named-content>\n            , which is one of the leading causes of community-acquired bacterial pneumonia (CABP). The evaluation of antimicrobial agents against\n            <jats:named-content content-type=\"genus-species\">H. influenzae<\/jats:named-content>\n            using standard murine infection models is challenging due to the low pathogenicity of this species in mice. Therefore, 24-h dose-ranging studies using a one-compartment\n            <jats:italic>in vitro<\/jats:italic>\n            infection model were undertaken with the goal of characterizing the magnitude of the ratio of the area under the concentration-time curve (AUC) to the MIC (AUC\/MIC ratio) associated with efficacy for a panel of five\n            <jats:named-content content-type=\"genus-species\">H. influenzae<\/jats:named-content>\n            isolates.\n          <\/jats:p>","DOI":"10.1128\/aac.02265-19","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T14:04:20Z","timestamp":1586441060000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment\n            <i>In Vitro<\/i>\n            Infection Model"],"prefix":"10.1128","volume":"64","author":[{"given":"Brian D.","family":"VanScoy","sequence":"first","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Lakota","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Conde","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McCauley","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Friedrich","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith N.","family":"Steenbergen","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata M.","family":"Bhavnani","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.129502"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61682-2"},{"key":"e_1_3_3_4_2","first-page":"1","article-title":"Deaths: leading causes for 2015","volume":"66","author":"Heron M","year":"2017","unstructured":"Heron M. 2017. Deaths: leading causes for 2015. Natl Vital Stat Rep 66:1\u201376.","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500245"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ1214"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17122120"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/430783"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02327-17"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq425"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv093"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01536-15"},{"key":"e_1_3_3_13_2","volume-title":"NUZYRA (omadacycline)\u00ae package insert","author":"Paratek Pharmaceuticals, Inc","year":"2020","unstructured":"Paratek Pharmaceuticals, Inc. 2020. NUZYRA (omadacycline)\u00ae package insert. Paratek Pharmaceuticals, Inc, Boston, MA."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02368-16"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00624-19"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.36.7.1412"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25232-y"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(02)00027-4"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2006.06.019"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00214-10"},{"key":"e_1_3_3_22_2","volume-title":"Pharmacokinetic-pharmacodynamics of delafloxacin against Haemophilus influenzae using data from a one-compartment in vitro infection model","author":"VanScoy BD","year":"2019","unstructured":"VanScoy BD, Conde H, McCurdy SP, Keedy K, Ambrose PG, Bhavnani SM. 2019. Pharmacokinetic-pharmacodynamics of delafloxacin against Haemophilus influenzae using data from a one-compartment in vitro infection model, poster no. T-10. American Society for Microbiology-European Society of Clinical Microbiology and Infectious Diseases, Boston, MA."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.44.4.943-949.2000"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/9781420017137.013"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00250-17"},{"key":"e_1_3_3_26_2","unstructured":"VanScoy BD Lakota EA Adams J Bhavnani SM Newman J Ambrose PG. 2017. Pharmacokinetics-pharmacodynamics of efficacy for eravacycline against Escherichia coli in an in vitro infection model poster no. Sunday-189. Microbe 2017 New Orleans LA 1 to 5 June 2017."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/653057"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.009"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.019"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.46.9.2956-2962.2002"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00484-15"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04955-14"},{"key":"e_1_3_3_33_2","doi-asserted-by":"crossref","unstructured":"Lakota EA Rodvold KA Bhavnani SM Steenbergen JN Tzanis E Ambrose PG Rubino CM. 2017. A pharmacometric comparison of omadacycline and tigecycline epithelial lining fluid (ELF) penetration abstr no. 63372. IDWeek Meeting San Diego CA 4 to 9 October 2017.","DOI":"10.1093\/ofid\/ofx163.1380"},{"key":"e_1_3_3_34_2","volume-title":"Guidance for industry. Community-acquired bacterial pneumonia: developing drugs for treatment. Draft guidance","author":"United States Department of Health and Human Services, Food and Drug Administration","year":"2014","unstructured":"United States Department of Health and Human Services, Food and Drug Administration. January 2014. Guidance for industry. Community-acquired bacterial pneumonia: developing drugs for treatment. Draft guidance. United States Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD."},{"key":"e_1_3_3_35_2","volume-title":"Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products","author":"European Medicines Agency, Committee for Medicinal Products for Human Use","year":"2016","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use. 2016. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products. European Medicines Agency, Committee for Medicinal Products for Human Use, London, United Kingdom."},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.010"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02307-18"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02309-18"},{"key":"e_1_3_3_39_2","unstructured":"Bhavnani SM Hammel SM Lakota EA Bader JC Bulik CC VanScoy BD Rubino CM Huband MD Steenbergen JN Ambrose PG. 2018. Pharmacokinetic-pharmacodynamic target attainment analyses evaluating omadacycline dosing regimens for the treatment of patients with community-acquired bacterial pneumonia for Streptococcus pneumoniae and Haemophilus influenzae . Microbe 2018 Atlanta GA 7 to 11 June 2018."},{"key":"e_1_3_3_40_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 11th ed. CLSI document M07-A11. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"11"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02513-12"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00656-13"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02265-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02265-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:46:04Z","timestamp":1645479964000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02265-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,5,21]]}},"alternative-id":["10.1128\/AAC.02265-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02265-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,21]]},"assertion":[{"value":"2019-12-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02265-19"}}